Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 2.5%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s stock price traded down 2.5% on Tuesday . The stock traded as low as $11.37 and last traded at $11.53. 33,077 shares were traded during mid-day trading, a decline of 91% from the average session volume of 387,633 shares. The stock had previously closed at $11.83.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Truist Financial initiated coverage on shares of Y-mAbs Therapeutics in a research note on Friday. They issued a “buy” rating and a $21.00 target price on the stock. Canaccord Genuity Group lifted their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. BMO Capital Markets boosted their price objective on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. Finally, HC Wainwright raised their target price on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, May 13th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat.com, Y-mAbs Therapeutics has an average rating of “Hold” and a consensus price target of $17.86.

Y-mAbs Therapeutics Stock Down 4.5 %

The stock has a 50-day simple moving average of $13.01 and a 200 day simple moving average of $12.90. The company has a market cap of $495.84 million, a PE ratio of -24.14 and a beta of 0.66.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $19.93 million during the quarter, compared to analysts’ expectations of $22.06 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. As a group, research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Insider Transactions at Y-mAbs Therapeutics

In related news, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the sale, the chief financial officer now owns 210,877 shares in the company, valued at approximately $2,545,285.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Thomas Gad sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total transaction of $300,000.00. Following the completion of the transaction, the insider now directly owns 240,032 shares of the company’s stock, valued at approximately $2,880,384. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Bo Kruse sold 31,371 shares of the company’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the sale, the chief financial officer now owns 210,877 shares in the company, valued at approximately $2,545,285.39. The disclosure for this sale can be found here. In the last three months, insiders have sold 99,444 shares of company stock worth $1,203,925. 21.50% of the stock is currently owned by insiders.

Institutional Trading of Y-mAbs Therapeutics

A number of large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new position in Y-mAbs Therapeutics in the fourth quarter worth approximately $34,000. Tower Research Capital LLC TRC raised its position in shares of Y-mAbs Therapeutics by 345.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,686 shares of the company’s stock worth $46,000 after acquiring an additional 5,185 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after purchasing an additional 1,056 shares during the last quarter. Bailard Inc. acquired a new position in Y-mAbs Therapeutics in the fourth quarter valued at approximately $115,000. Finally, SG Americas Securities LLC increased its stake in Y-mAbs Therapeutics by 17.5% in the fourth quarter. SG Americas Securities LLC now owns 21,559 shares of the company’s stock valued at $147,000 after purchasing an additional 3,210 shares during the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.